| Literature DB >> 35597973 |
Chin-Wei Kuo1,2, Chuan-Yu Chen3,4, Chih-Hsing Wu3, Chang-Wen Chen1, Fei-Ran Guo5,6, Szu-Chun Yang7.
Abstract
BACKGROUND: A cessation program for hospitalized smokers is an effective strategy to achieve smoking abstinence. The effects of multiple in-hospital counseling sessions on 6-month smoking abstinence require further investigation.Entities:
Keywords: Cessation counseling; Hospitalized smoker; Smoking cessation
Mesh:
Year: 2022 PMID: 35597973 PMCID: PMC9123762 DOI: 10.1186/s13722-022-00310-9
Source DB: PubMed Journal: Addict Sci Clin Pract ISSN: 1940-0632
Characteristics of smokers participating in a hospital-initiated cessation program
| Participants who censored ( | Participants for analysis ( | |||
|---|---|---|---|---|
| 6-month smoking abstinence | ||||
| Success ( | Failure ( | |||
| Age (years) | < 0.001 | |||
| < 65 | 789 (82.4) | 556 (71.5) | 981 (84.2) | |
| ≥ 65 | 168 (17.6) | 222 (28.5) | 184 (15.8) | |
| Sex | 0.237 | |||
| Male | 886 (92.6) | 716 (92.0) | 1054 (90.5) | |
| Female | 71 (7.4) | 62 (8.0) | 111 (9.5) | |
| Comorbiditiesa | < 0.001 | |||
| < 2 | 631 (65.9) | 405 (52.1) | 729 (62.6) | |
| ≥ 2 | 326 (34.1) | 373 (47.9) | 436 (37.5) | |
| Daily cigarette smoking | 0.011 | |||
| ≤ 20 | 275 (28.7) | 311 (40.0) | 400 (34.3) | |
| > 20 | 551 (57.6) | 467 (60.0) | 765 (65.7) | |
| Missing | 131 (13.7) | 0 (0.0) | 0 (0.0) | |
| FTND | < 0.001 | |||
| < 4 | 90 (9.4) | 109 (14.0) | 82 (7.0) | |
| 4 to 6 | 472 (49.3) | 411 (52.8) | 527 (45.2) | |
| ≥ 7 | 395 (41.3) | 258 (33.2) | 556 (47.7) | |
| Motivation | 0.769 | |||
| Self-motivated | 326 (34.1) | 207 (26.6) | 303 (26.0) | |
| Not self-motivated | 631 (65.9) | 571 (73.4) | 862 (74.0) | |
| Discharge diagnosis | < 0.001 | |||
| Cancer | 195 (20.4) | 157 (20.2) | 158 (13.6) | |
| CAD/HF | 165 (17.2) | 212 (27.3) | 207 (17.8) | |
| COPD/pneumonia | 22 (2.3) | 37 (4.8) | 40 (3.4) | |
| Others | 575 (60.1) | 372 (47.8) | 760 (65.2) | |
| ICU admission | < 0.001 | |||
| Yes | 213 (22.3) | 251 (32.3) | 156 (13.4) | |
| No | 744 (77.7) | 527 (67.7) | 1009 (86.6) | |
| Hospitalization | < 0.001 | |||
| ≤ 4 days | 456 (47.6) | 336 (43.2) | 637 (54.7) | |
| > 4 days | 501 (52.4) | 442 (56.8) | 528 (45.3) | |
| Cessation medications | 0.175 | |||
| No use | 823 (86.0) | 673 (86.5) | 1020 (87.6) | |
| NRT | 75 (7.8) | 56 (7.2) | 81 (7.0) | |
| Non-NRT | 22 (2.3) | 31 (4.0) | 28 (2.4) | |
| NRT and non-NRT | 37 (3.9) | 18 (2.3) | 36 (3.1) | |
| Number of in-hospital counseling | 0.001 | |||
| 1 | 773 (80.8) | 616 (79.2) | 995 (85.4) | |
| 2 | 113 (11.8) | 104 (13.4) | 117 (10.0) | |
| ≥ 3 | 71 (7.4) | 58 (7.5) | 53 (4.6) | |
CAD coronary artery disease, COPD chronic obstructive pulmonary disease, FTND Fagerstrom test for nicotine dependence, HF heart failure, ICU intensive care unit, NRT nicotine replacement therapy
aComorbidities include cardiovascular disease, cancer, cerebral vascular disease, diabetes mellitus, hypertension, liver disease, respiratory system disease, and renal disease
Multiple logistic regression analyses
| Covariablesa | Main analysis ( | Censored participants ( | Excluding participants with out-patient cessation ( | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Adjusted OR (95% CI) | Adjusted OR (95% CI) | Adjusted OR (95% CI) | |||||||
| Age ≥ 65 years | 1.78 (1.40–2.28) | < 0.001 | 1.29 (0.98–1.69) | 0.073 | 1.72 (1.34–2.20) | < 0.001 | |||
| Male | 1.04 (0.73–1.49) | 0.839 | 1.10 (0.79–1.51) | 0.579 | 1.02 (0.71–1.46) | 0.920 | |||
| ≥ 2 comorbiditiesb | 1.25 (1.01–1.53) | 0.037 | 1.17 (0.97–1.41) | 0.099 | 1.27 (1.03–1.58) | 0.026 | |||
| Daily cigarette smoking > 20 | 1.09 (0.86–1.38) | 0.487 | 0.75 (0.62–0.90) | 0.003 | 1.09 (0.85–1.39) | 0.492 | |||
| FTND | |||||||||
| < 4 | Reference | Reference | Reference | ||||||
| 4 to 6 | 0.49 (0.34–0.69) | < 0.001 | 0.69 (0.47–1.01) | 0.056 | 0.45 (0.32–0.64) | < 0.001 | |||
| ≥ 7 | 0.28 (0.19–0.42) | < 0.001 | 0.50 (0.30–0.84) | 0.009 | 0.27 (0.18–0.41) | < 0.001 | |||
| Self-motivated | 1.19 (0.95–1.50) | 0.139 | 0.67 (0.49–0.91) | 0.012 | 1.20 (0.96–1.54) | 0.098 | |||
| Discharge diagnosis | |||||||||
| Others | Reference | Reference | Reference | ||||||
| Cancer | 2.18 (1.66–2.86) | < 0.001 | 1.67 (1.32–2.13) | < 0.001 | 2.19 (1.67–2.87) | < 0.001 | |||
| CAD/HF | 1.40 (1.04–1.88) | 0.028 | 1.24 (0.95–1.62) | 0.110 | 1.35 (0.99–1.85) | 0.058 | |||
| COPD/pneumonia | 1.58 (0.96–2.61) | 0.073 | 1.32 (0.82–2.12) | 0.252 | 1.45 (0.83–2.56) | 0.195 | |||
| ICU admission | 2.82 (2.14–3.73) | < 0.001 | 2.41 (1.89–3.06) | < 0.001 | 2.84 (2.13–3.78) | < 0.001 | |||
| Hospitalization > 4 days | 1.43 (1.15–1.77) | 0.001 | 1.19 (0.98–1.45) | 0.076 | 1.46 (1.17–1.82) | 0.001 | |||
| Cessation medications | |||||||||
| No use | Reference | Reference | Reference | ||||||
| NRT | 1.12 (0.74–1.68) | 0.599 | 1.05 (0.73–1.52) | 0.784 | 1.10 (0.70–1.73) | 0.684 | |||
| Non-NRT | 1.60 (0.89–2.86) | 0.115 | 1.42 (0.85–2.38) | 0.180 | 1.83 (0.93–3.59) | 0.081 | |||
| NRT and non-NRT | 0.80 (0.42–1.51) | 0.484 | 0.81 (0.46–1.45) | 0.485 | 0.97 (0.48–1.97) | 0.927 | |||
| Number of in-hospital counseling | < 0.001 | 0.010 | 0.012 | ||||||
| 1 | Reference | Reference | Reference | ||||||
| 2 | 1.44 (1.05–1.98) | 0.025 | 1.21 (0.92–1.61) | 0.180 | 1.43 (1.03–1.98) | 0.034 | |||
| ≥ 3 | 2.02 (1.27–3.22) | 0.003 | 1.82 (1.21–2.73) | 0.004 | 1.62 (0.98–2.66) | 0.059 | |||
CAD coronary artery disease, CI confidence interval, COPD chronic obstructive pulmonary disease, FTND Fagerstrom test for nicotine dependence, HF heart failure, ICU intensive care unit, NRT nicotine replacement therapy, OR odds ratio
aReferences for covariables: age (≥ 65 versus < 65), sex (male versus female), number of comorbidities (≥ 2 versus < 2), number of cigarettes smoked daily (> 20 versus ≤ 20), FTND score (≥ 7 and 4–6 versus < 4), motivation (self-motivated versus not self-motivated), main discharge diagnosis (cancer, CAD/HF, COPD/pneumonia versus without), ICU admission (yes versus no), length of hospital stay (> 4 days versus ≤ 4 days), and cessation medications (NRT, non-NRT, and both versus no)
bComorbidities include cardiovascular disease, cancer, cerebral vascular disease, diabetes mellitus, hypertension, liver disease, respiratory system disease, and renal disease